• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Mersana Therapeutics Inc. (Amendment)

    2/14/24 8:56:11 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRSN alert in real time by email
    SC 13G/A 1 tm246235d18_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Mersana Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    59045L106

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

     

    x

     

    ¨

    Rule 13d-1(b)

     

    Rule 13d-1(c)

     

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 59045L106Page 2 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    11,328,000 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    11,328,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,328,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,978,132 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 297,926 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,051,942 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 120,582,114 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

     

     

    CUSIP No. 59045L106Page 3 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    11,328,000 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    11,328,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,328,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,978,132 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 297,926 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,051,942 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 120,582,114 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

     

     

    CUSIP No. 59045L106Page 4 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    11,328,000 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    11,328,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,328,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,978,132 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 297,926 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,051,942 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 120,582,114 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

     

     

    CUSIP No. 59045L106Page 5 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    11,328,000 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    11,328,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,328,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,978,132 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 297,926 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,051,942 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 120,582,114 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

     

     

    CUSIP No. 59045L106Page 6 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    11,328,000 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    11,328,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,328,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,978,132 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 297,926 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,051,942 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 120,582,114 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

     

     

    CUSIP No. 59045L106Page 7 of 14

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    11,328,000 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    11,328,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,328,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

    9.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,978,132 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 297,926 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,051,942 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 120,582,114 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

     

     

    CUSIP No. 59045L106Page 8 of 14

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    11,328,000 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    11,328,000 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,328,000 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.4% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 2,978,132 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 297,926 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,051,942 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 120,582,114 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

     

     

    CUSIP No. 59045L106Page 9 of 14

     

    Introductory Note:  This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of Mersana Therapeutics, Inc.

     

    Item 1.
      (a)

    Name of Issuer

     

    Mersana Therapeutics, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    840 Memorial Drive

    Cambridge, MA 02139

     
    Item 2.
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     
      (b)

    Address of Principal Business Office or, if none, Residence

         
        New York Office: Palo Alto Office:
         
        7 Bryant Park 3340 Hillview Avenue
        23rd Floor Palo Alto, CA 94304
        New York, NY 10018  
     
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.0001 par value

     
      (e)

    CUSIP Number

     

    59045L106

     

     

    CUSIP No. 59045L106Page 10 of 14

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

    Item 4. Ownership
       
      (a)

    Amount beneficially owned as of December 31, 2023:

     

    Venrock Healthcare Capital Partners III, L.P.   11,328,000 (1) 
    VHCP Co-Investment Holdings III, LLC   11,328,000 (1) 
    Venrock Healthcare Capital Partners EG, L.P.   11,328,000 (1) 
    VHCP Management III, LLC   11,328,000 (1) 
    VHCP Management EG, LLC   11,328,000 (1) 
    Nimish Shah   11,328,000 (1) 
    Bong Koh   11,328,000 (1) 

     

      (b)

    Percent of class as of December 31, 2023:

     

    Venrock Healthcare Capital Partners III, L.P.   9.4% (2) 
    VHCP Co-Investment Holdings III, LLC   9.4% (2) 
    Venrock Healthcare Capital Partners EG, L.P.   9.4% (2) 
    VHCP Management III, LLC   9.4% (2) 
    VHCP Management EG, LLC   9.4% (2) 
    Nimish Shah   9.4% (2) 
    Bong Koh   9.4% (2) 

     

      (c)

    Number of shares as to which the person has, as of December 31, 2023:

        (i) Sole power to vote or to direct the vote:

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

     

    CUSIP No. 59045L106Page 11 of 14

     

        (ii) Shared power to vote or to direct the vote:

     

    Venrock Healthcare Capital Partners III, L.P.   11,328,000 (1) 
    VHCP Co-Investment Holdings III, LLC   11,328,000 (1) 
    Venrock Healthcare Capital Partners EG, L.P.   11,328,000 (1) 
    VHCP Management III, LLC   11,328,000 (1) 
    VHCP Management EG, LLC   11,328,000 (1) 
    Nimish Shah   11,328,000 (1) 
    Bong Koh   11,328,000 (1) 

     

        (iii) Sole power to dispose or to direct the disposition of:

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

        (iv) Shared power to dispose or to direct the disposition of:

     

    Venrock Healthcare Capital Partners III, L.P.   11,328,000 (1) 
    VHCP Co-Investment Holdings III, LLC   11,328,000 (1) 
    Venrock Healthcare Capital Partners EG, L.P.   11,328,000 (1) 
    VHCP Management III, LLC   11,328,000 (1) 
    VHCP Management EG, LLC   11,328,000 (1) 
    Nimish Shah   11,328,000 (1) 
    Bong Koh   11,328,000 (1) 

     

    (1)Consists of (i) 2,978,132 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 297,926 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,051,942 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

    (2)This percentage is calculated based upon 120,582,114 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
             

     

    CUSIP No. 59045L106Page 12 of 14

     

    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.
             

     

    CUSIP No. 59045L106Page 13 of 14

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024 

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
             
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
             
    VHCP Co-Investment Holdings III, LLC      
             
    By: VHCP Management III, LLC      
    Its: Manager      
             
    By: /s/ Sherman G. Souther      
      Name: Sherman G. Souther      
      Its: Authorized Signatory      
             
    VHCP Management III, LLC   VHCP Management EG, LLC
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
             
    Nimish Shah      
           
    /s/ Sherman G. Souther      
    Sherman G. Souther, Attorney-in-fact      
             
    Bong Koh      
           
    /s/ Sherman G. Souther      
    Sherman G. Souther, Attorney-in-fact      

     

     

    CUSIP No. 59045L106Page 14 of 14

     

    EXHIBITS

     

    A: Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on August 7, 2023)

     

    B: Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed August 7, 2023)

     

    C: Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on August 7, 2023)

     

     

     

    Get the next $MRSN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MRSN

    DatePrice TargetRatingAnalyst
    2/6/2025Outperform
    William Blair
    11/15/2024$5.00Buy
    Citigroup
    3/19/2024$5.00Underweight → Neutral
    JP Morgan
    2/29/2024$6.00Neutral → Buy
    BTIG Research
    2/29/2024$7.00Neutral → Buy
    Guggenheim
    2/29/2024$2.00 → $7.00Neutral → Outperform
    Wedbush
    12/4/2023$1.00 → $5.00Neutral → Buy
    Citigroup
    7/28/2023$7.00 → $1.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $MRSN
    SEC Filings

    See more
    • Mersana Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

      7/3/25 4:10:34 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

      6/13/25 4:22:01 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

      6/2/25 8:23:21 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Leadership Updates

    Live Leadership Updates

    See more
    • Mersana Therapeutics Announces Changes in Leadership

      Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the retirement of Anna Protopapas, President and CEO, effective September 10, 2023, and the

      9/6/23 7:00:40 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Provides Statement About SVB

      CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana's capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company's capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB. Mersana has a loan and security agreement with Oxford Finance LLC and SVB. As previously

      3/10/23 7:10:38 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership

      CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana's pri

      10/25/21 8:00:00 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Alleva Lawrence M

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      6/13/25 5:15:12 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hack Andrew A. F.

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      6/13/25 5:10:40 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dere Willard H

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      6/13/25 5:02:42 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

      31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced additional interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660), the company's B7-H4-directed Dolasynthen ADC. These data are being presented in an oral session today at the American Socie

      6/2/25 8:10:31 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics to Present at Upcoming Investor Conferences

      CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events: TD Cowen 6th Annual Oncology Innovation SummitFormat:         Fireside chatDate/Time:   Tuesday, May 27, 2025, at 2:00 p.m. Eastern TimeGoldman Sachs 46th Annual Global Healthcare Conference Format:        PresentationDate/Time:  Monday, June 9, 2025, at 2:00 p.m. Eastern Time Live webcasts of these events will be available on the I

      5/20/25 8:00:59 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

      In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ:MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been 5.7 months rather than 1.7 months. The corrected release follows: Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate dosesEncouraging preliminary time-to-event data in triple-negative breast cancer (

      5/15/25 9:20:09 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Mersana Therapeutics

      William Blair initiated coverage of Mersana Therapeutics with a rating of Outperform

      2/6/25 7:08:59 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup resumed coverage on Mersana Therapeutics with a new price target

      Citigroup resumed coverage of Mersana Therapeutics with a rating of Buy and set a new price target of $5.00

      11/15/24 8:15:56 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics upgraded by JP Morgan with a new price target

      JP Morgan upgraded Mersana Therapeutics from Underweight to Neutral and set a new price target of $5.00

      3/19/24 7:51:31 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Mersana Therapeutics Inc.

      SC 13D/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/15/24 4:45:57 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

      SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/14/24 5:45:55 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

      SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/14/24 6:01:51 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Financials

    Live finance-specific insights

    See more
    • CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

      In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ:MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been 5.7 months rather than 1.7 months. The corrected release follows: Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate dosesEncouraging preliminary time-to-event data in triple-negative breast cancer (

      5/15/25 9:20:09 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

      Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate dosesEncouraging preliminary time-to-event data in triple-negative breast cancer (TNBC) Second, higher dose recently selected for expansion in post-topoisomerase-1 inhibitor ADC (post-topo-1) TNBC; patient enrollment advancing in both dose expansion cohorts Plan to report initial clinical data from expansion in second half of 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a

      5/15/25 7:00:40 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

      Cost-saving initiatives expected to extend company's cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the implementation of a strategic restructuring and reprioritization plan aimed at extending the company's cash runway and furthering the development of emiltatug ledad

      5/6/25 7:00:51 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care